Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD, Parkinson's, and Alzheimer's, emphasizing a transformative approach to immune balance restoration.
The initiative is part of Stellantis's strategy to increase its vehicle production in Italy to 1 million units by 2030, up from approximately 750,000 last year.